

Data Sharing Statement

Singh. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. *JAMA*. Published April 14, 2020. 10.1001/jama.2020.3138

Data

Data available: Yes

Data types: Other (please specify)

Additional Information: Deidentified stored samples will be made available on a case by case basis after the request is approved by the steering committee (N Singh, AP Limaye and M Boeckh). Decisions will be made by the steering committee based on scientific merit and sample availability. Requests should be submitted in writing to Dr.Nina Singh(nis5@pitt.edu) or Dr.Ajit P.Limaye (alimaye@medicine.washington.edu). Samples will be made available only to researchers whose proposed use of samples has been approved by the steering committee and with a signed data access agreement. Prioritization will be for NIH (or other governmental agency)-funded studies. Samples will be shared only after ongoing secondary, tertiary, and other analyses have been performed by study team members and if there is remaining sample. The steering committee has the ultimate decision in approving or denying sample sharing

How to access data: Requests should be submitted in writing to Dr.Nina Singh(nis5@pitt.edu) or Dr.Ajit P.Limaye (alimaye@medicine.washington.edu).

When available: beginning date: 01-31-2021, end date: 01-01-2022

Supporting Documents

Document types: None

Additional Information

Who can access the data: Samples will be made available only to researchers whose proposed use of samples has been approved by the steering committee. Prioritization will be for NIH (or other governmental agency)-funded studies.

Types of analyses: Samples will be available for a specified purpose to be communicated in writing to Dr.Singh or Dr.Limaye.

Mechanisms of data availability: Samples will be made available only to researchers whose proposed use of samples has been approved by the steering committee and with a signed data access agreement.

Prioritization will be for NIH (or other governmental agency)-funded studies. Samples will be shared only after ongoing secondary, tertiary, and other analyses have been performed by study team members and if there is remaining sample.

Any additional restrictions: The Steering committee has the ultimate decision in approving or denying sample sharing.